Index

beta-cells (β-cells) (continued)
- mass, 116–17
- in T2DM, 103, 354–5, 357, 358, 361
- meglintide effects, 616–18
- metabolism, 96–9
- oxidative phosphorylation, 97, 420
- origin of new cells in adult, 64
- pathophysiology, 103
- regeneration, 73, 356–8
- regulation of growth, 64–5
- sulfonylurea effects, 616–18
- in transplantation of pancreas or islets, function, 777
- β-granule, 89, 91, 101
- exocytosis/insulin secretion, 99, 100–1
- abnormalities, 103, 364
- β-oxidation see fat
- Betâ (Neuroni), 61, 83, 84, 85
- bevacizumab in retinopathy, 900–1
- Beta2 (Neurod1), 61, 83, 84, 85, 877
- -oxidation exocytosis/insulin secretion, 99, 100–1
- sulfonylurea effects, 616–18
- pathophysiology, 103
- meglitinide effects, 616–18
- body mass index (BMI)
- in neuropathy prevention, 568–70
- in neuropathy, 965
- in poorly-controlled T2DM, 388
- in cranial and central nervous system, 388
- edema complicating diabetes ketoadisis, 801–2
- energy balance and, 529–37
- components, 675–6
- in pregnancy complicated by diabetes, 829
- calorie, 44
- current recommendation in diabetes, 578, 580–1
- diet low in see low-carbohydrate diets
- thiazolidinedione effects, 666–7
- thyroid, and GLP-1 agonists, 738
- Cancer Prevention Study II (CPS II), 306, 308
- candesartan, retinopathy, 898
- CAP-Ch1 complex, 172–4
- capillary electrophoresis–mass spectroscopy, 1116
- neuropathy detection, 913–14
- carbamylated hemoglobin, 863
- carbohydrate diet, 44
- current recommendation in diabetes, 578, 580–1
- diet low in see low-carbohydrate diets
- inhibitors of intestinal digestion and absorption of, 710
- in nonalcoholic fatty liver disease management, 293–4
- see also sugar
- metabolism, ketoadisis and, 801–2
- carbohydrate responsive element binding protein (C/EBP), 207, 264
- carboxypeptidase E (CP-E), 533
- carboxypeptidase H (CP-H), 89–91
- CARD1a (Coronary Artery Revascularization in Diabetes) study, 1074
- cardiosmyopathy, 941–2, 1068–9
- cardiovascular disease (CVD), 1007–1011
- burden, 1031–2
- deaths see mortalities
- diabetes therapy and its impact on risk of, 1070–3
- dysplasiamia and, 262–3
- endothelium and see endothelium
eutrophil dysfunction and risk of, 980, 982
- HbA1c and risk of, 859–60
- hyperglycemia and see hyperglycemia
- insulin resistance and, 346
- nephropathy and risk of, 923
- nonalcoholic fatty liver disease and risk of, 289
obstructive sleep apnea and, 329–40
older adults, risk factor reduction, 839
periodontal disease and, 997
mucopolysaccharidosis type I, 15

α-glucosidase inhibitors, 678
DPP-4 inhibitors, 737
GLP-1 receptor agonists, 737
sultfonylureas, 631
thiazolidinediones, 664–5
GLP-1 effects, 152, 727
hypoglycemia adverse effects, 790
CARDIS (Collaborative Atorvastatin Diabetes Study) trial, 265, 267, 268, 922
CARE (Cholesterol and Recurrent Events) trial, 268
T2DM, 449
Centrals (Collaborative Atorvastatin Diabetes Study) trial, 265, 267, 268, 922
see
Obesity, energy expenditure in, 482–3
Nonalcoholic fatty liver disease, 286–8
Ketoacidosis, 801
Hyperosmolar state, 801, 805–6
see
Glucose dysregulation, prevalence in different ethnic groups, 35

INDEX
cognitive - behavioral therapy (CBT) (continued) eating disorders, 848, 848 – 9 cognitive (neurocognitive) impairment, 849 elderly, 839 – 40 colestevam, 269, 758 – 61 colestipol, 269 Collaborative Atorvastatin Diabetes Study (CARD), trial, 265, 267, 268, 922 collaborative management see multidisciplinary team collagen (skin) and Rosenbloom syndrome, 960 colon and colorectal cancer ir-glucosidase inhibitors and, 680 T2DM and, 307, 309, 310, 311 – 12 colony-stimulating factor, granulocyte see granulocyte-colony stimulating factor coma, laboratory evaluation, 806 combination drug therapy (incl. adjunctive/add-on), 689 – 98 ir-glucosidases, 675 – 60 biguanides see biguanides dipeptidyl-peptide-4 inhibitors see dipeptidyl-peptide-4/DPP-4 inhibitors GLP-1 receptor agonists see glucagon-like peptide-1 (GLP-1) receptor agonists/analogues in hypertension, 1086 in inadequately controlled onset T2DM, 694 – 8 insulin see insulin administration in newly diagnosed and new onset T2DM, 689 – 94 sulfonylureas see sulfonylureas thiazolidinediones see thiazolidinediones triple, 693 – 4, 696 – 8 comorbid conditions HbA1c tests affected by, 862 – 3 obstructive sleep apnea, 324 – 30 older adults, 839, 840 T2DM in children, 42 complications (of diabetes), 872 – 1101 advanced glycosylation end-products and see advanced glycosylation bariatric surgery effects, 510 – 11 connective tissue, 953 – 63 economic cost, 1114, 1115, 1116 exercise and, 603 – 4 HbA1c and, 859 – 60 macrovascular see macrovascular disease microvascular see microvascular complications periodontal disease effects on, 987 retinopathy and its relationship with other types of, 892 – 3 stroke prevention, 1098 T1DM, acute, 24 T2DM children, 42 obstructive sleep apnea and, 327 see also comorbid conditions computed tomography and CT angiography, atherosclerosis, 1035 CONCEPT study, 831 corneal microscopy, corneal, 933 – 4 congenital malformations with diabetes in pregnancy, 827 – 8 detection, 831 insulin lispro and, 830 congestive heart failure, thiazolidinedione and monitoring of patients with, 668 connective tissue disorders, 953 – 63 constitutional factors, Rosenbloom syndrome, 960 – 1 continence problems see incontinence continuous glucose monitoring/sensing/CGM (subcutaneous), 769, 785, 831 added to pumps, 752 in hyperglycemic crises, 813 linked to/integrated with pumps, 750 – 2 pregnancy, 831 continuous infusion of glucose with model assessment (CGMA), 341 of insulin intravenously, in hyperosmolar state and ketoacidosis management, 808 – 9, 813 subcutaneously see insulin pump continuous positive airway pressure (CPAP) in obstructive sleep apnea, 316, 323, 324, 327, 330, 331 contraception, postpartum, 833 contraction of muscle, 174 Convention on the Elimination of All Forms of Discrimination against Women, 1107, 1108 Convention on the Rights of the Child, 1106, 1108 Convention on the Rights of Persons with Disabilities, 1107–8 cornea confocal microscopy, 933 – 4 disorders, 933 coronary heart disease (CHD; CAD; coronary artery disease), 1011 – 15, 1064 – 8 atherosclerosis, 1010, 1035, 1067 clinical features, 1067 – 70 endothelial progenitor cells and, and 1047 exercise (in diabetics) and, 603 key practical features of relationship between diabetes and, 1084 – 7 management strategies, 1073 – 4 microvascular, 1070 postprandial lipemia and, 266 – 7 prevalence and incidence, 1011 – 12 prognosis, 1065 – 6 revascularization after CV event, 1074 risk factors, 1013 – 15, 1017 see also acute coronary syndromes, myocardium, infarction corpus cavernosum in erectile dysfunction changes within, 976 – 7 drugs injected into, 983 – 4 corticosteroids see steroids cost (economic/financial) of diabetes care, 1113 – 24 direct, 1114, 1115 drivers, 1116 estimating, 1114 – 16 global perspectives, 1113 – 24 indirect, 1114, 1116 periodontal disease and, 987 – 8 cost-effectiveness, 1118 – 21 gestational diabetes screening, 824 – 5 prevention, 1119 – 21 T2DM, 557 – 8 cost-utility analysis, 1118 counterregulatory hormones to insulin see insulin COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, 1074 covalent modification of enzymes in regulation of gluconeogenesis, 200 cow’s milk, 22, 544 cranial nerve neuropathies causing ocular motility disorders, 902 – 3 Cre-lox technology, 521, 522, 523, 531 CREB see cAMP-response element binding protein (look under AMP) critical illness, protein metabolism, 258 critical limb ischemia, 1992, 1097 CREC2 (CAMP-regulated transcriptional co-activator), 198 CTLA-4 gene, 446, 460 cyclic AMP see AMP cyclin(s), 65 cyclin-dependent kinase(s) (Cdk), 65 CDK2/NA2/B gene region, 404, 408 PPAR agonists and, 658 T2DM and, 404, 407, 408 cyclin-dependent kinase inhibitors (CkIs), 65 cyclosporin T1DM prevention, 545 – 6 T1DM therapy, 541 – 2 cyst(s), renal, and diabetes (RCAD syndrome), 435, 436 cystic fibrosis-related diabetes, 10, 74 cytochrome P450 enzymes bromocriptine - QR and, 667 thiazolidinediones and, 667 cytotoxicity, 59 – 62 cytokines adipose tissue-secreted see adipokines proinflammatory, 886 cancer and T2DM and, 310 periodontal disease and, 983 cytokine, GLUT4 translocation and, 178 cytosol proteins, O-linked glycosylation, 418 – 19 D Da Qing trial, 43, 552, 553, 838 Daf genes, 183 DAFNE (Dose Adjustment For Normal Eating) program, 793 dairy products, optimal amounts, 585 DAISY (Diabetes Autoimmunity Study in the Young) study, 19, 20, 21, 22, 23, 463 dapagliflozin and metformin, 693 daycare exposure to infection, T1DM and, 22 db/db mice, 311 – 12, 521 deafness, maternally inherited diabetes and (MIDD), 7, 427, 435, 436 – 7 deaths see mortalities debridement, foot wounds, 969 decision support for older adults with diabetes, 842 DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia) study, 30, 31, 32, 33, 34, 35, 36, 37 DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) study, 29, 30, 31, 32, 35, 36, 551, 1018, 1020 dehydroepiandrosterone (DHEA), 721 DELAY trial, 542 delivery of baby, timing and mode, 832 – 3 delta (δ)-cells (somatostatin-producing), 61, 71, 102, 115 dementia and hypoglycemia, 630 demethylasterrigine, 716 demyelinating polyradiculoneuropathy, chronic inflammatory (CIDP), 931, 932 DEND syndrome (developmental delay, epilepsy and neonatal diabetes), 434 dendritic cell therapy, T1DM, 543 – 4 dental care co-management of and medical care providers and providers of, 999 guidelines for practitioners, 1000 recommendations for patients, 1000 2-deoxyglucose, 127 deoxyglucoses, 865 depression, 846 – 7 elderly, 840 screening, 850 dermal collagen and Rosenbloom syndrome, 960 DETAIL (Diabetes Exposed to Telmisartan and Enalapril), 567 developed (higher-income) countries
cost-saving and cost-effective interventions for, 1114, 1121
risin prevalence, 39
developing (lower-income) countries epidemiological and expenditure data, 1112
individuals and families paying care costs, 1116
Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes, 577
Diabetic Atlas (International Diabetes Federation), 836, 1122
Diabetes Autoimmunity Study in the Young (DAISY) study, 19, 20, 21, 22, 23, 463
Diabetes Control and Complications Trial (DCCT), 22, 419, 415, 421, 565, 568, 570, 767, 769, 777, 790, 795
connective tissue disorders, 960
coronary heart disease, 1066, 1070
EDIC and, 566, 767, 899, 876, 920, 948, 1034
foot disorders, 965, 967
HbA1c and, 856, 859
microvascular complication prevention, 565, 566, 859
nephropathy, 565, 919, 920
neuropathy, 568
autoimmune, 940
retnopathy, 570, 898, 899
Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia (DECODE) study, 30, 31, 32, 33, 34, 35, 36, 37
Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study, 29, 30, 31, 32, 35, 36, 551, 1018, 1020
DIABETES Genetics Replication and Meta-analysis (DIAGRAM) study, 404, 407
Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Studies, 1018, 1020
Diabetes Prevention Program (DPP), 43, 267, 469, 496, 500, 552, 555, 559, 648, 663, 838, 940
Diabetes Prevention Program Outcomes Study (DPPOS), 648
Diabetes Prevention Study (DPS) in Finland, 43, 552, 554, 558, 559
Diabetes Prevention Trial-Type 1 (DPT-1), 21, 22, 254
"diabetic foods", 578, 583
Diabetic Retinopathy Vitrectomy Study (DRVS), 902
Diabetes Exposed to Telmisartan and Enalapril (DETAIL) study, 567
diacylglycerol (DAG), 102, 180
cardiovascular disease and, 1036, 1039
diacylglycerol transferase and its inhibitors, 485
DIAD (Detection of Ischemia in Asymptomatic Diabetics) study, 1073
diagnosis (and detection), 11–13
cardiovascular autonomic neuropathy, 942–43
Charcot neuroarthropathy, 972
diabetes, 11–13
HbA1c in ex hemoglobin A1c
maternally inherited diabetes and deafness, 437
maturity-onset diabetes of the young, 428, 430, 432
in pregnancy, 13, 824–4, 828–9
T1DM, 21
T2DM see type 2 DM early see early diagnosis and detection gastrointestinal autonomic neuropathy, 944–5
hyperosmolar state, 800, 807–8
ketoadsisisis, 800, 803–4
metabolic (insulin resistance) syndrome, 347–8, 1033, 1034, 1046
nephropathy, 914
obstructive sleep apnea, 318–19
periodontal disease, 989–90, 989–92
peripheral vascular disease, 1092–3
renal cysts and diabetes syndrome, 436
Wolfram syndrome, 437
see also screening
DIAGRAM (DIABETES Genetics Replication and Meta-analysis) study, 404, 407
diabetes
exercise and, 604
foot disease and, 967
DiaPep277 (heat shock protein 60-derived peptide), 543
diabetes
diabetic function/dysfunction, 1070
DDMOAD (Wolfram syndrome), 7, 427, 435, 437
diet and nutrition, 577–85
current recommendations, 578
elderly people, 837–8
Europe and North America, management in diabetes, 577–85
exercise and, 603
autonomic neuropathy, management, 945
hypertension management, 1083, 1085
implementation of diet therapy, 583–7
insulin resistance and, 345
nephropathy, 913
neurogenic diabetic liver disease management, 267
combined with exercise, 294–6
combined with weight-loss medication, 296
surgical methods, 296–9
obesity-induced diabetes (animal models) and cancer and, 312–13
obesity interventions (for weight loss), 267, 489–91
pregnancy complicated by diabetes, management, 829
T1DM and, 22–3
infant, and HLA class II alleles, 23
infant, and prevention of T1DM, 23, 544–5
management, 577, 597, 580, 587
T2DM and, 43
management, 267, 475–6, 577, 578, 579, 580, 587
management in combination with α-glucosidase inhibitors, 675
preventive use, 552, 553
thermosensitivity induced by, 481
see also fed state; food, malnutrition, supplements; weight, loss
diffusion chamber bio-artificial pancreas, 771
DIGAMI (Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction) Studies, 1013, 1065, 1070, 1073
dipeptidyl-peptidase-4 (DPP-4)
doubly-labelled water method, 480
DPP-4 see dipeptidyl-peptidase-4
dipeptidyl-peptidase-4 inhibitors
DRCRnet (The Diabetic Retinopathy Clinical Research Network), 899, 900, 901
DRED study, 555, 556, 663
fibrin, 1052–4
fibrin digestion, 1068
fibrinogen, 1065–7
circadian and diurnal
DNA methylation, 409, 435, 876, 913
transcription see transcription
DOK family, 168
dopaminergic activity of bromocriptine, 761
dorsal pancreatic bud induction, 58
dorsalis pedis pulse and peripheral vascular disease, 1092
Dose Adjustment For Normal Eating (DAFNE) program, 793
doubly-labelled water method, 480
DPP-4 see dipeptidyl-peptidase-4
dipeptidyl-peptidase-4 inhibitors
DRCRnet (The Diabetic Retinopathy Clinical Research Network), 899, 900, 901
drug-based prevention
neuropathy prevention, 565–8
neuropathy prevention, 570
retinopathy prevention, 570–1
T2DM, 499, 554–7
α-glucosidase inhibitors, 556, 676–7
lifestyle vs., 557
metformin, 554–6, 648
thiazolidinediones, 556, 663
thrombosis, 1058–9
drug-based therapy (pharmacotherapy), 615–764
autonomic neuropathy
cardiovascular, 943, 944
gastrointestinal, 945–6
cardiovascular event risk, 1073
Charcot neuroarthropathy, 972–3
combinations see combination drug therapy
dyslipidemia, 267–70
rationale, 265–7
erectile dysfunction, 982–4
future prospects, 985
existing approved agents, 712
metabolic syndrome, 350
neonatal diabetes, 434
new agents, 709–25, 727–8, 758–64
development process, 709, 710
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, 292, 297–301
combined with diet, 296
obesity, 496–502
peripheral vascular disease, 1094–6, 1096–7
in pregnancy see pregnancy
retinopathy, 898–9
T1DM
α-glucosidase inhibitors, 674, 677–8
trials, 541–6
T2DM see type 2 DM
transcription factor MODY, 432
weight-loss, 296, 496–502, 648–9, 678
drug-based therapy (pharmacotherapy) (continued) see also pharmacometabolomics, polypharmacy and specific (types of) drugs
drug-eluting coronary stents, 1074 drug-induced conditions diabetes, 8–9 hyperemnosial state, 801, 807 ketoadisis, 801 encitrate dysfunction, 979 drug interactions bromocriptine-QR, 762–3 coleselavam, 761 thiazolidinediones, 667 DRVS (Diabetic Retinopathy Vitrectomy Study), 902 dulaglutide, 714, 728

viii Index
function
incretin-based therapies in patients with impaired filtration rate, 740
thiazolidinedione effects, 665
structural changes in nephropathy, 917–18
GLOWS (glucose-lowering effect of WelChol Study), 759
glucagon, 136–44, 371 – 2, 387
amino acid composition, 136–7
as counterregulatory hormone, 140 – 1, 721
diabetes and, 141, 156
gene, 137, 138
in hypoglycemia, defective response (including with diabetes treatment), 786
insulin gene expression inhibited by, 85
intramuscular injections in hypoglycemia, 792
islet cells producing α-cell or α-cells
β-cell (along with insulin), 364
metabolic effects, 139, 217
physiologic effects, 138–9
receptors, 102, 138
antagonists, 721
null mutants, 141
secretion/release (and subsequent levels/concentrations), 139–40
control, 139–40
GIP effects, 152, 156
GLP-1 effects, 147, 150, 156, 727
incretin effects, 146
octreotide effects, 721
PACAP effects, 128
sulfonylurea effects, 622
glucagon-like peptide-1 (GLP-1), 112–13, 137–8, 414–15, 522
secretion/release (and subsequent levels/concentrations), 139–40
control, 139–40
GIP effects, 152, 156
GLP-1 effects, 147, 150, 156, 727
incretin effects, 146
octreotide effects, 721
PACAP effects, 128
sulfonylurea effects, 622
insulin gene expression, 101, 113, 149–50, 155–6, 471, 727
in T2DM, 154–5, 155–6
glucagon-like peptide-1 (GLP-1) receptor agonists/analogues (μ-incretin mimetics), 501–2, 628, 714, 726, 727–32, 877
antibody formation, 732
combinatorial linkage with GIP analogues, 715
combined with other drugs, 728–9
one other drug, 660, 661, 696
two other drugs, 691
concerns and expectations, 737–40
development, 727–8
newer/future agents, 728, 742
DOP-4 inhibitors compared with, 736
existing approved, 712
gastrointestinal adverse effects, 731, 732, 946
glucose-lowering effects, 728–31
microvascular complication prevention, 877
in nonalcoholic fatty liver disease, 298–9
recommendations and guidelines on use of, 740–2
special patient groups, 739–40
structures, 741
T2DM prevention, 557
weight loss properties, 501–2, 731–2
glucagon-like peptide-2 (GLP-2), 138
gut barrier function in obesity and, 476
glucagonoma syndrome, 142
glucocorticoids see steroids
glucokinase (GCK; hexokinase IV), 204–5, 206, 207, 226, 239–40, 383, 878
β-cell, 96
activators, 713
mutations causing MODY (GCK-MODY), 7, 374, 426, 428–30
glucooxidoreductase (glucose synthesis from non-carbohydrate sources), 99, 139, 196–204, 215, 217
diabetic ketoacidosis and, 802
hepatic, 139, 193, 194–5, 196–204, 206, 208, 215, 378, 644
exercise and, 590
fatty acids as substrate, 202, 203, 216–17
obesity and T2DM and, 470, 522
pathways, 196–8
hepatic, drugs affecting, 722
bromocriptine-QR and, 761
fibroblast growth factor, 217
first phase insulin response to IV administration, 21, 375
homeostasis/regulation/control, 371–2
bariatric surgery and, 91, 112
β-cell function and, 119, 374–5
brain (incl. hypothalamus) and, 529–37
glucagon in, 140–1, 371–2
in hypoglycemia, 785–6
impaired see fasting glucose; glucose intolerance
O-glycosylation of nuclear and cytosolic proteins and, 418–19
obese adolescents and, 819
metformin effects, 648–9, 714, 726, 727, 1069
obesity and, 472–3
impaired, 789
liver, 204–204, 216
from non-carbohydrate carbon substrates see gluconeogenesis
renal, 216, 379
thrombosis and effects of, 1056
toxicity see glucotoxicity
transport, 169–79, 211, 226
biguanide effects, 644–5
cardiomypathy and, 1069
insulin resistance and abnormalities in, 180, 383
PI-3 kinase-dependent, 169–72
PI-3 kinase-independent, 172–5
proteins see glucose transporters
renal reabsorption, 387
see also sodium–glucose transport protein
utilization and uptake
hyperglycemia and, 414
ketoadiposis and, 802
liver, 204, 228
T2DM and
obese adolescents and, 819
prevention of T2DM in patients with IGT, 558
sulfonylurea and, 643–5
insulin secretions and, 644–5, 691
biguanide effects, 644–5
polycystic ovary syndrome and, 649
pathogenesis, 385–7
prevalence
ethnicity-related, 35–9
in low-income countries, 1122
ratio of diabetes to, 36
sex-related prevalence, 36
T2DM and
obese adolescents and, 819
prevention of T2DM in patients with IGT, 558
sulfonylurea and, 643–5
insulin secretions and, 644–5, 691
biguanide effects, 644–5
polycystic ovary syndrome and, 649
pathogenesis, 385–7
prevalence
ethnicity-related, 35–9
in low-income countries, 1122
ratio of diabetes to, 36
sex-related prevalence, 36
T2DM and
obese adolescents and, 819
prevention of T2DM in patients with IGT, 558
sulfonylurea and, 643–5
insulin secretions and, 644–5, 691
biguanide effects, 644–5
polycystic ovary syndrome and, 649
pathogenesis, 385–7
prevalence
ethnicity-related, 35–9
in low-income countries, 1122
ratio of diabetes to, 36
sex-related prevalence, 36
T2DM and
Index

glucose-lowering (hypoglycemic) agents (continued)
retinopathy, 898
in pregnancy see pregnancy
subcutaneous see subcutaneous administration
thrombosis prevention, 1058, 1059
see also specific (types of) glucose-lowering drugs
glucose tolerance
impaired see glucose intolerance
unipaired, HbA1c in patients with, 855–7
-glucosylation
see also
fingers
continued
-glycosylation
see also

-amylose inhibitors, 675–85
clinical applications, 674–8
prevention of T2DM, 536, 676–7
weight loss properties, 500, 678
combined with other drugs, 675–6
contraindications, 680
dose recommendations, 681
dose – response relationships, 675
existing approved, 680–1
mechanism of action, 673–4
other beneficial effects, 678–9
reversible competitive, 710
tolerability/adverse effects, 679–80
see also specific drugs
glucotoxicity (of chronic hyperglycemia), 85–6, 87, 376, 413–25, 1036–8
-β-cell and failure, 420
loss, 75
clinical significance, 421
definition and terminology, 413
molecular mechanisms, 417–21
GLUT see glucose transporters
glutamic acid decarboxylase (GAD) antigen, 4, 20, 401, 543
vaccine, 543
glyceride and metformin in T2DM, 646, 690
in pregnancy, 830
glycation, 854
advanced see advanced glycosylation
hemoglobin see hemoglobin A1c reactions, 854
serum proteins, 863–4
thrombosis and effects of, 1056
glycemia (blood/plasma glucose)
age- and sex-specific concentrations, 30
1,5-anhydroglucitol as measure of, 865
bedside point-of-care monitoring with hyperglycemic crises, 813
classification related to levels of, 4
continuous monitoring see continuous glucose monitoring
control (interventional) see glycemic control control (physiologic)
sche glucose, homeostasis conversion factors for glucose concentrations,
29–30
estimated average glucose (eAG) in HbA1c assessment, 856–7
vs. mean blood glucose, 857
fasting see fasting glucose
self-monitoring (SMBG), 749–50, 751, 752, 856
HbA1c as adjunct to, in pregnancy, 859, 864–5
see also dysglycemia; hyperglycemia; hypoglycemia;
normoglycemia
glycemic control (interventional)
-α-glucosidase inhibitors and, 674, 675
biguanides and, 645
cardiovascular disease and, 1033–4
colesevelam and, 758–9
in diabetic ketoacidosis, targets, 810, 813
erectic dysfunction and, 980–1
exercise and, 605, 606
gastric emptying in improvement of, modulation of, 946
HbA1c in T1DM as unique index of, 858
intensive, recent emphasis on, 630
metabolic memory phenomenon see metabolic memory
microvascular disease prevention and, 375
nephropathy prevention, 565
neuropathy prevention, 568–70
older adults, 839
peridontal care and, 998
peridontitis and poor levels of, 993–4
in pregnancy, 828–9
adverse outcomes related to poor levels of, 827–8
in labor, 833
retinopathy prevention, 570
sulfonlureas and, 625, 630
thiazolidinediones and, 560
glycemic index, 44
current recommendations in diabetes, 578, 580–1
means for various foods, 582
glyceraldehyde and glutathione, 197
glycogen
breakdown (glycogenolysis) in liver, 194, 195–6
drugs affecting, 722
exercise and, 591–2
ketone bodies and, 802
regulation, 196
synthesis, 227, 381, 384–5
- ketosidase and, 802
liver, 195, 196, 205–6
training and, 598
therapeutic targeting of metabolism, 206
glycogen phosphorylase, 196, 206, 225, 381
exercise and, 591–2
inhibitors, 722
glycogen synthase kinase (GSK)
GSK-3, 87, 171, 196, 205, 206, 225, 381, 722
inhibitors, 722
glycogen synthase phosphatase (muscle protein phosphatase 1/PP-1), 381, 384
glycolysis, 96–7, 206–8
-β-cell, 96–7
mutations affecting, 426
ketoadocidosis and, 802
liver, 196, 206–8
as therapeutic target, 207
microvascular complication prevention and, 878
glycopenia in the brain, 785–6
glycoprotein IIb/IIIa receptor see Gplibl/IIa receptor
glycoursia in transcription factor MODY, 432
glycorylation, 18–19, 882–3
advanced see advanced glycosylation
definition, 855
GLUT4, 177
N-linked see N-glycosylation
O-linked, 418–19
glyxanalase, 883
Golgi apparatus, proinsulin transport from ER to, 89
Gplibl/IIa receptor, 1052, 1053
inhibitors, 1059
gains see breakfast cereals, cereals
granulocyte-colony stimulating factor (GCSF)
foot ulcer therapy, 970
T1DM therapy, 543
Grb2, 381
growth
fetal, assessment, 831–2
Rosenbloom syndrome and, 957
growth factors
-β-cell growth, 64–5
in foot ulcer treatment, 970
GCSFs (GLUT4 storage vesicles), 176, 177, 178, 179, 213
GTPases, RAB family, 100, 174, 177–8
gums see gingiva
-gut (gastrointestinal tract - incl. stomach and intestine)
autonomic neuropathy, 943, 944–6
drug side effects
-α-glucosidase inhibitors, 679
GLP-1 receptor agonists, 731, 732, 946
metformin, 651
microbiota see microbiota
obesity-linked diabetes and, 469–78
-gut hormones/peptides, 471–3
advanced glycosylation inhibitor effects on secretion, 678
appetite and satiety and, 471, 508–9, 727
gastrin production, 153
GLP effects on, 152–3
insulin secretion and, 471
K cell production of GIP, 1080–9, 927
foot ulcer therapy, 970
L cells producing see L cells
obesity-linked diabetes and, 472–3
S cell production of, 152–3
-gut tube patterning into organs, 57–8
-gynoid vs. android obesity, 68
H
hand(s), disorders affecting, 955–7, 958
see also fingers
Handan Eye study, 891
HAPO (Hyperglycemia and Adverse Pregnancy Outcome) study, 13, 826, 858
haptoglobin and hypertension, 1080
HDL see high-density lipoprotein
health policy-makers, cost-effectiveness and, 1119
right to, 1106–7, 1107, 1108, 1110
health insurance, USA, 1116–17
Healthy People Curriculum Task Force, 1001
hearts
arthrythmias see arrhythmias
coronary disease see coronary heart disease
microvascular disease, 1070
muscle see myocardium
see also cardiomyopathy
heart failure, 1070
thiazolidinedione and monitoring of patients with, 668
Heart Outcomes Prevention Evaluation (HOPE) study, 1097
heat preservation see thermogenesis
heat shock protein 60-derived peptide (DnaPep277), 543
Helsinki Heart Study (HHS), 270
hematopoietic stem cell therapy, autologous, 544
hemodialysis
exercise and, 604
foot disease and, 967
hemodynamic pathways and microvascular complications, 879–80
hemoglobin A, 855
hemoglobin A0, 855
hemoglobin A1c (glycated hemoglobin; HbA1c), 854–63
artificial pancreas and, 866–7
complications of diabetes and, 859–60
diagnostic use, 11–12, 21, 857
in pregnancy, 858
drugs effects on levels of sulfonylureas, 624
DPP-4 inhibitors, 733–6
GLP-1 receptor agonists, 728–31
PPAR-y agonists and other drugs, 660
measurement/assay, 11–12, 21, 855–9
comorbid illness affecting, 862–3
frequency, 862
methods, 860–1
standardization, 856
nephropathy and, 919, 920
nomenclature, 855
normal glucose tolerance and, 855–7
in older adults, self-management in improvement of, 841
periodontal therapy effects on levels of, 862–3
pre-diabetes and, 851
in pregnancy, 858
screening for, 858
target values, 829
process (glycation reactions), 854–5
kinetics, 855
retinopathy and, 859, 898
screening use see screening
in T1DM, as unique index of glycemic control, 858 total, 855
methods of measuring, 861
hemoglobin C trait and HbA1c testing, 862
hemoglobin E trait and HbA1c testing, 862
hemoglobin F and HbA1c testing, 862, 863
hemoglobin S/Sβ/SC and HbA1c testing, 862, 863
hemoglobinopathies and HbA1c testing, 862
hemorrhage, subarachnoid, 1015–16
hemorrhagic stroke, 1015, 1097
hemostasis, 1051–63
components involved, 1052–3
heparin thromboprophylaxis, 1059
hepatectomy (hepatocellular) gluconic effects, 139
triglycerides, sources, 284–6
hepatectomy nuclear factor 1A (HNF1A) and hepatectomy nuclear factor 4A (HNF4A) gene
β-cell response influenced by, 115
erectile dysfunction, 977–9
exercise metabolism and, 591–2
sex hormones see sex hormones
islet see islets
obstructive sleep apnea and, 324
see also endocrinopathies; neuroendocrine system
and entries under endocrine
hormone-sensitive lipase (HSL) and exercise, 591–2
hospitalizations, periodontal care effects on, 998
HPS2-THRIVE trial, 266
human immunodeficiency virus see HIV disease
human leukocyte antigens see HLA
human rights, 1105–12
hyaline change in glomerulus in nephropathy, 918
hydration in ketosacidosis and hyperosmolar state, 808
hydrocolloids, 970
hydrogels, 970
β-hydroxybutyrate, 805, 810
3-hydroxy-3-methylglutaryl-CoA inhibitors see statins
1,11-dihydroxy steroid dehydrogenase-1 inhibitors, 721
5-hydroxytryptamine (serotonin) 2C (5-HT2C) receptor agonist, selective, 499
hygiene and T1DM, 22
hyperamylasemia in ketoadosis, 805
hyperfiltration in nephropathy, 913–16
hyperglycemia (elevated glucose), 413–25, 876–9,
1009, 1033–4
acute stimulatory effect, 414
cancer and, links between, 309
cardiovascular disease and, 1033–4
asymptomatic hyperglycemia and CVD risk, 1017–20
blood pressure and, 1009, 1082
long-term hyperglycemia and cardiovascular mortality, 1014
stroke damage in presence of hyperglycemia, 1017
chronic/long-term, 413–25, 876–9
cardiovascular mortality and, 1014
glucotoxicity of see glucotoxicity
impaired insulin secretion caused by, 416–17
in T1DM, 421
in T2DM, 421
crises (in hyperosmolar state and ketoacidosis)
future prospects in management of, 813
management after resolution of, 811–12
prevention, 812–13
treatment, 808–10
diagnosis of diabetes and other categories of, 12
exercise-related, in T1DM and T2DM, 602
fasting see fasting hyperglycemia
gene regulation and, 876–7
microvascular complications and, 876–9
retinopathy, 892, 893
NF-kB activation and, 1038
in nonalcoholic fatty liver disease, 288–9
obese, 804, 808
pathophysiology, 413–17
hepatic glucose and inhibition of its production, 216
postprandial see fed state
in pregnancy diagnosis, 827
thrombosis and, 1056
tissue memory of see metabolic memory
see also dysglycemia
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, 13, 826, 858
hyperglycemic clamp technique, 110–11
hyperglycemic hyperosmolar state (HHS), 805–8
definitions, 805
800–87–8
hyperglycemic hyperosmolar state (HHS) (continued)
- epidemiology, 805
- management, 808–13
- future prospects, 813
- hyperglycemic crises see hyperglycemia
- mortalities, 799, 805
- pathogenesis, 807
- precipitating and predisposing factors, 801, 805–6
- water and electrolyte metabolism, 803
- hyperinsulinemia, 234, 1009
- atherogenesis and, 1038
- blood pressure and, 1009–10, 1079, 1080, 1082
- glucose production, 215
- GF-1 1, 309
- in nonalcoholic fatty liver disease, 288–9
- hypertriglyceridemia
- hypertension, arterial (high BP), 892, 1007–11, 1079–90
- bariatric surgery effects, 511
- etiology/pathogenesis, 1008–10, 1080–3
- bariatricsurgeryeffects, 511
- immunosuppressive drugs, T1DM therapy, 541–2, 544
- clinical use, 738–9
- concerns and expectations, 737–40
- future developments, 742
- nonpeptide mimetics, 715
- peptide mimetics see glucagon-like peptide-1
- [GLP-1] receptor agonists/analougues special patient groups, 739–40
- secretions, 148–9
- see also specific hormones
- 'increment effect', 112–13, 145–8, 153–6, 471
- in health, 145–8
- impairment (increment defect/dysfunction), 153–6, 361–3, 377
- diabetes, 153–6, 361–3, 377, 473
- obesity, 363
- India
- costs paid by individual and family, 1116
- retinopathy prevalence in southern region, 891
- T2DM prevalence, 32, 36–8
- individual (patient), costs paid by, 1116–17
- infant diet and T1DM
- HLA class II alleles and, 23
- prevention of T1DM, 23, 344–5
- see also neonates
- infections (caused in pathogenesis)
- diabetes, 6, 9
- T1DM, 22, 23, 446–7, 461
- T2DM animal studies, 520
- hyperosmolar state, 807
- ketoacidosis, 800
- obesity, animal studies, 520
- infections (complication), diabetic foot, 968–9
- inflammation, 44, 885
- atherosclerosis and, 1038
- cardiovascular disease and erectile dysfunction and, 980
- cytokines involved in see cytokines
- gut microbiota and, 474
- inflammatory cell infiltration, 885–6
- insulin resistance and, 1033
- islet, 76
- metabolic, and adiposity, 1040–2
- periodontal disease and, 992, 993
- retinopathy and, 893
- thiazolidinedione effects, 667
- thrombosis and, 1057
- inflammatory demyelinating polyradiculoneuropathy, chronic (CIDP), 931, 932
- information see education and information
Index xv

intrinsic see genetic defects and factors; genetic
inhibitor Kß kinase-ß (IKKß), 181–2, 719, 886
insulin, injection site issues, 795
intracereosal in erectile dysfunction, 93–4
Înkea and Înkle, 65
innervation
islet, 72, 116, 125–32
sudomotor see sudomotor innervation
D-chiro-inositol-galactosamine, 718
D-chiro-inositol, 718
insulin (biology/physiology), 161–280
action/effects/roles, 161–280, 522, 531–4
animal studies, 522
changing perspectives, 163–4
hyperinsulinemia
days, 719
energy homeostasis, 531–5
food intake, 531–2
insulin deficiency and, 161–280, 522, 531–4
minimal model, 238–40
modulation, 180–2
multiple roles, 339–40
normal physiology of, 161–280, 522, 531–4
prenatal exposure to higher
fasting glucose levels
exercise and, 591–2
glycemic control, 522, 531–4
aerobics, 163
atrial atrial natriuretic peptide and see atrial natriuretic peptide
bariatric surgery effects on, 512
pregnancy, 830
safety, 830
systemic effects, 830
short-acting, 830
mutations, 82–3
animals, 531–4
animal studies, 522
insulin resistance (IR) in T1DM, 414
insulin resistance (IR) in T2DM or
470, 686, 819–20, 1008–9, 1036–42
animal studies, 522–4
atherosclerosis, 163
bariatric surgery effects, 511–12
blood pressure and, 1008–9, 1079, 1080, 1083
chronic hyperglycemia as cause of, 414–16
defining, 339
dopaminergic tone and, 761
dyslipidemia see dyslipidemia
endothelium and see endothelium
glycated transport abnormalities and, 180, 383
consequences, 288
hexosamine biosynthetic pathway and, 416–17
insulin signaling impairment and, 179–80, 379–80, 381, 879
measuring, 234–49, 340, 341–2
HOMA see Homeostasis Model Assessment
neuropeptides, 275–80
metformin effects, 648
muscle, 372, 379, 687–8, 819
obesity and, 470, 474
obese, 819
obstructive sleep apnea and, 319–23
oxidative stress and, 423
pathways linked to, 342–7
periodontal disease and, 992, 993, 994, 996
simple characteristics associated with, 340–2
smoking and, 45
therapeutic approaches, 265–70
see also Trimovibate
Insulin Resistance Atherosclerosis Study (IRAS), 1011, 1035
insulin resistance syndrome see metabolic syndrome
insulin response elements (IREs), 182–3
insulin secretion (by ß-cell), 96–107, 108
bariatric surgery and, 512
drugs augmenting/increasing/potentiation
(secretagogues), 713–16
combined with metformin, 647
see also meglitinides, sulfonylureas
mutations, 99–100
abnormalities, 103
first phase (in response to IV glucose), 21, 375
hypoglycemic (GIIS), 97–102, 114–15
gut hormone effects, 411–2
 incretins see subheading below
impaired, 374, 375–7, 416–17
animal studies, 522
macrovascular disease/complications (continued) biguanides, 646–8 see also cardiovascular disease and specific types of macrovascular complications macular edema, 894, 897 treatment, 899, 900, 901, 902 MAF, 61, 83–4, 84, 85, 86, 87, 420 MalB, 61, 83–4 MAGIC (Meta-Analyses of Glucose- and Insulin-related traits Consortium), 404, 407 magnesium hypertension and, 1081 supplements, 720 magnetic resonance imaging Charcot neuroarthropathy, 972 functional see functional MRI Maillard reaction, 854, 882, 960 major histocompatibility complex antigens see HLA malate–aspartate (MA) shuttle, 98 major histocompatibility complex antigens Charcot neuroarthropathy, 972–3 macrovascular disease/complications (continued) malnutrition adult, diabetes related to, 5 maternal and fetal, 377, 520 management (incl. interventions/treatment/care), 575–87 albumin levels in urine see albuminuria; macroalbuminuria; microalbuminuria autonomic neuropathy autonomic neuropathy, 945–6 cardiovascular, 943–4 cardiovascular risk related to, 1070–3 cell-based see cell-based therapies Charcot neuroarthropathy, 972–3 collaborative see multidisciplinary team coronary heart disease, 1073–4 cost see cost; cost-effectiveness; cost-utility dyslipidemia, 265–70, 722 erectile dysfunction, 947, 980–5 foot ulcers, 969–71 hyperglycemic hyperosmolar state see hyperglycemic hyperosmolar state hypoglycemia, 791–4 ketoacidosis see ketoacidosis less-than-optimal, consequences, 1117 lifefood, 1001 lifestyle see lifestyle maternal inherited diabetes and deafness, 437 maturity-onset diabetes of the young glucokinase MODY, 430 transcription factor MODY, 432 metabolic syndrome, 350 neonatal diabetes permanent, 434 transient, 435 nephropathy management, 919–23 nonalcoholic fatty liver disease, 292–305 obesity, see also obesity obstructive sleep apnea, 330 older adults see aging persons patient-led see self-management periodontal disease, effects on diabetes of, 996–7 peripheral vascular disease, 1083–7 pharmacological see drug-based prevention; drug-based therapy in pregnancy see pregnancy quality, improving, 1117, 1118 renal cysts and diabetes syndrome, 436 retinopathy, 897, 898–902 surgical, see also surgery T1DM and T2DM see type 1 DM; type 2 DM mandibular advancement devices, 330 MAP kinase see mitogen activated protein kinase Mapuche of Chile, 35 mass spectrometry and metabolomics, 277 MATCH (Management of Atherothrombosis with Clopidogrel in High-risk patients with recent TIA or ischemic stroke) Trial, 1098 maternal... (as in pregnancy) see pregnancy maternally inherited diabetes and deafness (MIDD), 7, 427, 435, 436–7 maturity-onset diabetes of the young (MODY), 374, 427–33 diagnosis, 428 mutations causing, 7 glucokinase (GCK-MODY), 7, 374, 426, 428–30 transcription factor (TF-MODY), 374, 426, 428, 429, 431–3 subtypes/phenotypes, 428–33 MCP-1 (monocyte chemotactant protein), 1041 meat, optimal amounts, 585 median nerve compression at carpal tunnel (w carpel tunnel syndrome), 955, 958 medical care (and periodontal disease) costs, 987–8 dental care and, co-management between providers of, 999 Medical Research Council/British Heart Foundation Heart Protection Study (MRC/BHF HPS), 267 Medtronic Minimed implantable insulin pump, 753, 754–5, 769 medullary thyroid carcinoma and GLP-1 agonists, 738 meglitinides (glinides), 613–40, 711 chemistry and structure, 618–19 combined with other meformin, 689, 690–1, 694–5 existing approved, 712 mechanism of action, 616–18 prevention of T2DM, 556 in "treat-to-fail" approach, 694–5 Melanoma, T2DM age and sex-specific prevalence, 34 melatonin receptors, 407, 1080 Melbourne Visual Impairment Project, 890 men coronary heart disease, 1012 acute myocardial infarction fatalities, 1013 erectile dysfunction see erectile dysfunction menopause, exercise and diabetes after, 597 mental health professionals, 850 see also psychological problems metabolic acidosis, laboratory values, 806 metabolic endotoxemia, 474, 476 metabolic inflammation and adiposity, 1040–2 metabolic memory phenomenon/effect, 409, 570, 767, 876 coronary heart disease management and the metabolic component, 1074–5 retinopathy and, 898, 899 metabolic rate low, as cause of obesity, 482–3 resting, 481 metabolic syndrome (Meth; insulin resistance syndrome; syndrome X; Reaven’s), 339–53, 1032–3, 1046–50 atherogenesis and, 1032–3, 1036–42 coronary heart disease and, 1064 current thinking regarding, 350–1 diagnostic criteria for (and definition of), 347–8, 1033, 1034, 1046 endothelium and, 1046–50 nonalcoholic fatty liver disease and, 283, 285, 286, 287, 288, 343 pathogenesis, 1033, 1036–8 purpose of concept of, 348–9 treatment, 350 Metabolic Syndrome Cancer (Me-Can) European cohort, 309 metabolism (and biochemistry) abdominal fat, and obese adolescents, 819 β-cell see β-cells dietary interventions (in obesity and T2DM) affecting, 475–6 drug effects on biguanides, 643–5 thiazolidinediones, 662–4 in exercise, 590–2 in diabetics, 592–6 protein, 256–7 glucagon effects, 139, 217 ketoacidosis and, 801–3 older adults, alterations, 837 peroxisome proliferator-activated receptor effects, 558 PI-3 kinase and insulin effects on, 169–71 retinopathy and, 893 Rosenbloom syndrome and, 960–1 see also specific substrates metabolomics and T2DM and insulin resistance, 273–80 metacarpophalangeal joints (MCJs) in Rosenbloom syndrome, 956, 957 metformin see biguanides methylation DNA, 409, 435, 876, 913 histone, 520, 876 methylglyoxal, 883 microalbuminuria, 346, 911, 914, 915, 916, 1008, 1085 exercise and, 604 management, 567, 585, 665, 918–19, 920, 921, 1085 obstructive sleep apnea and, 329 screening for, 918–19 microbiota, 473–6 bariatric surgery effects, 513 in health, 473 obesity and T2DM and, 473–6 animal studies, 520–1 and dietary interventions, 475–6 short chain fatty acids and, 474, 524–5 Micronutra, T2DM age and sex-specific prevalence, 34 micronutrients, dietary recommendations, 583 supplements, 720 see also minerals; vitamins microparticles, endothelial release, 1047 microRNAs, 408, 877 nephropathy and, 917 microsomal triglyceride transfer protein (MTP), 263, 264 microvascular complications/disease, 875–951 bariatric surgery effects, 510–11 HbAlc and, 859 heart, 1070 neuropathy genesis and the role of, 930 obstructive sleep apnea and, 327 pathogenesis see pathogenesis prevention/risk reduction, 564–73 α-glucosidase inhibitors, 678–9 biguanides, 646–8, 877 strict glycemic control in see glycemic control Rosenbloom syndrome associated with, 939–40 see also specific microvascular complications Middle East, T2DM age and sex-specific prevalence, 34 miglitol, 673, 674, 675, 676, 710
nerve fibers (axons) in neuropathy, atrophy, 928–9
glia, dysfunction, 929
intraperitoneal (IPN), 932–3, 934
methylated, 928–9
unmethylated, 930
nervous system: autonomic see autonomic nerves β-cell response influenced by, 115–16 central see brain (incl. cerebrum and central nervous system) safety/appetite and, 308–9 see also neuroendocrine system neuritis, painful peripheral, drugs causing erectile dysfunction in, 979 neuroarthropathy, Charcot, 972–3 neuropsychiatric impairment see cognitive impairment neurodiology (βeta), 61, 83, 84, 85 neuroendocrine system in exercise, 591 in polycystic ovary syndrome, defects, 591 NeuroQ3, 60–1

neuroglycopenia, 785–6
Nkx2.2, 61–2

nitric oxide (NO), 266, 269
nitrated tyrosine (NIT) see dopamine, nitration NOD see non-obese diabetes (NOD) OPA see ocular pathology OPA1 see optic neuropathy OSA see obstructive sleep apnea and Obese see obesity (adiposity -and over-/excess weight) oral health, 999

oral health problems see periodontal disease oral insulin in T1DM prevention, 544 oral glucose challenge test in gestational diabetes screening, 826 oral glucose-lowering agents see glucose-lowering agents oral glucose tolerance test (OGTT), 110, 111–12, 113, 242–4, 341 pregnancy, 826 gestational diabetes, 824, 825, 826 in T2DM, 21 in T2DM, 358 oral health, 999 care/procedure provision, 998, 999, 1000 patient guidelines, 998–9

problems see periodontal disease oral insulin in T1DM prevention, 545 organic cation transporters (OCT) of SLC22A gene family and biguanides, 642...
paracrineopathy of islets of Langerhans, diabetes as, 136, 141
paraffollicular (C-cell) carcinoma and GLP-1 agonists, 728
parasympathetic nerves erectile dysfunction and, 976
islets, 125–6, 128
physiologic roles, 132
see also autonomic nerves; parasympathetic nerves; sympathetic nerves
paraciliates in nephropathy, 923
Paris Prospective Study, 1012, 1014, 1018
PAS (Per-Arnt-Sim) kinase, 84, 87
pasta, glycemic index, 582
patatin-like phospholipase domain containing 3 protein (PNPLA3) I148M variant, 286, 287–8
pathogenesis (and pathophysiology), 339–46, 1036–42
atherosclerosis, 1035–42
autonomic nephropathy, 939–41
cardiac, 1067
gastrointestinal, 944
hypertension in diabetics, 1088–9
in elderly persons, 837
foot ulcers, 964–6
hyperglycemia see hyperglycemia
hyperosmolar state, 807
hypertension in diabetics, 1088–9, 1080–3
ketoadiposis, 801
metabolic syndrome, 1033, 1036–8
microvascular complications, 375–88
retinopathy, 893
nonalcoholic fatty liver disease, 284–8
obstructive sleep apnea (OSA), 318
peripheral neuropathy, 926, 931, 965
T2DM, 442–66
T2DM, 339–412
T2DM, 718–20
T2DM, 1065, 1097

peripheral vascular/arterial disease (incl. occlusion/atherosclerosis), 1091–7
diagnosis, 1092–3
treatment, 1093–7
PERISCOPE study, 666
periarticular delivery of insulin, 753, 768, 786
periarticular dialysis and exercise, 604
peroxisome proliferator-activated receptor-α (PPARα), 658, 1089
agonists see fibrates
cardiomyopathy and, 1069
omega-3 polyunsaturated fatty acid effects, 298
peroxisome proliferator-activated receptor-γ (PPARY), 270, 657, 660, 719–20
peroxisome proliferator-activated receptor-γ (PPARY), 658–60, 719–20
agonists see thiazolidinediones
co-activator 1 (PPG1-1), 183, 198, 199–200, 386
as T2DM candidate gene, 403
PGC-1 (PPARY co-activator 1), 183, 198, 199–200, 386
PH (pleastrin) domain of receptor substrate/docking proteins, 166, 167, 168
pharmacological agents see drug-based prevention;
drug-based therapy; polypharmacy
pharmacometabolomics, 279
phase 1–4 trials of new drugs, 710
phenotypes maturity-onset diabetes of the young (MODY), 428–33
thrifty, 551
phterminone, obesity, 497–8
phterminone/topramate (Qsymia®), 497–8
in nonalcoholic fatty liver disease, 296
in obesity, 497
phentolamine, intracavernosal, 983
phosphate deficiency and replacement in diabetic
ketoacidosis and hyperosmolar state, 811
phosphatidyl-1-lysine 3-phosphate (PE(1L)), 102–3, 169–72, 213, 225, 251, 253, 257
atherosclerosis and, 1038
degradation/impairment of signal, 172, 382
leptin and insulin and, 530, 533
phosphatidylinositol 4,5,6-trisphosphate (PIP3), 530, 718
dephosphorylation, inhibition, 718
phosphodiesterases 3B (PDE-3B) inhibitors, 716
phosphodiesterase 5 (PDE5) inhibitors, 718
erectile dysfunction, 982–3, 984
nephropathy prevention, 568
phosphoenolpyruvate carboxykinase (PEPCk)
β-cell, 99
liver, 182, 183, 198, 199, 200, 202
biguanides and, 644
phosphofructokinase (PFK), 202, 206–7, 227, 385

relationships between diabetes and, 993–9
effects of diabetes interventions on periodontitis in T2DM, 995
effects of diabetes on periodontal disease, 994–5
effects on diabetes complications of periodontal disease, 997
effects on diabetes of periodontal disease, 995–6, 1001
effects on diabetes of periodontal disease treatment, 996–7
self-reported, 982
peripheral immune tolerance, 446
peripheral neuritis, painful, drugs causing erectile dysfunction in, 979
peripheral neuropathy see neuropathy
peripheral vascular disease, 1096
peroxisome proliferator-activated receptor-α (PPARα), 658, 1089
agonists see fibrates
cardiomyopathy and, 1069
omega-3 polyunsaturated fatty acid effects, 298
peroxisome proliferator-activated receptor-γ (PPARY), 658–60, 719–20
agonists see thiazolidinediones
co-activator 1 (PPG1-1), 183, 198, 199–200, 386
PH (pleastrin) domain of receptor substrate/docking proteins, 166, 167, 168
pharmacological agents see drug-based prevention;
drug-based therapy; polypharmacy
pharmacometabolomics, 279
phase 1–4 trials of new drugs, 710
phenotypes maturity-onset diabetes of the young (MODY), 428–33
thrifty, 551
phterminone, obesity, 497–8
phterminone/topramate (Qsymia®), 497–8
in nonalcoholic fatty liver disease, 296
in obesity, 497
phentolamine, intracavernosal, 983
phosphate deficiency and replacement in diabetic
ketoacidosis and hyperosmolar state, 811
phosphatidyl-1-lysine 3-phosphate (PE(1L)), 102–3, 169–72, 213, 225, 251, 253, 257
atherosclerosis and, 1038
degradation/impairment of signal, 172, 382
leptin and insulin and, 530, 533
phosphatidylinositol 4,5,6-trisphosphate (PIP3), 530, 718
dephosphorylation, inhibition, 718
phosphodiesterases 3B (PDE-3B) inhibitors, 716
phosphodiesterase 5 (PDE5) inhibitors, 718
erectile dysfunction, 982–3, 984
nephropathy prevention, 568
phosphoenolpyruvate carboxykinase (PEPCk)
β-cell, 99
liver, 182, 183, 198, 199, 200, 202
biguanides and, 644
phosphofructokinase (PFK), 202, 206–7, 227, 385
Index

3-phosphoinositide-dependent kinase-1 (PKC δ), 171, 172, 253, 330, 333
phosphorylation
glucose, 226, 7, 383–4
as therapeutic target, 205
GLUT4, 177
glycogen phosphorylase, 196
glycogen synthase, 196, 205
insulin receptor, 180
oxidative see oxidative phosphorylation
photocoagulation (laser), retinopathy, 899
photography, retinopathy, 895
screening use, 897
physical activity see exercise
physical disability, elderly, 841
physical examination see examination
physician (clinician) see knowledge of cost-effectiveness and cost-utility, 1119
oral health guidelines, 1000
physician office visits and oral health, 998, 1000
Physicians’ Health Study, 306, 309, 310
physician (clinician) see knowledge of cost-effectiveness and cost-utility, 1119

polygenic (multigenic) disorder
hypertension as, 1079, 1080
T2DM, 11, 401, 434, 455
T2DM as, 11, 426
polymorphisms (gene), 1080
ACE (angiotensin-converting enzyme), 1015, 1080
glycogen synthase, 384, 1080
HLA, 20, 444, 456
insulin, 85, 445
plasminogen activator inhibitor, 1 1053
PNPLA3 I148M variant, 286, 287–8
single-nucleotide see single-nucleotide polymorphisms
Polynesia, T2DM age and sex-specific prevalence, 34
polypeptide see polypeptide
polypeptide
polypeptide
polypeptide polymorphisms
postpartum period (women)
preeclampsia, 62–5
postpartum state, 810–11, 812
postnatal (child) β-cell growth and maintenance, 62–5
postpartum period (women)
care in, 833
contraception, 833
postpartum state see fed state
postembryonic development of, 881–2
postnatal period (women)
replacement therapy in diabetic ketoacidosis, 810–11
see also hypokalemia
potassium
levels in diabetic ketoacidosis and hyperosmolar state, 810–11, 812
replacement therapy in diabetic ketoacidosis, 810–11
see also hypokalemia
potassium (K⁺) channels
ATP-sensitive potassium see ATP-sensitive potassium channels
candidate genes and mutations, 404, 427
neonatal diabetes, 434
poultry, optimal amounts, 585
prebiotics, 474, 476
precipitating factors
hyperosmolar state, 801, 805–6
ketoadiposis, 800–1
preconception care in gestational diabetes, 820
pre-diabetes, 550–1
HBA1c and, 857
obstructive sleep apnea and, 319
orlistat, 499
screening in coronary heart disease patients, 1066–7
predisposing factors see causes
pregestational (pre-existing) diabetes, 824
HBA1c target values, 829
HBA1c testing, 858–9
preconception care, 820
pregnancy, 823–35
adverse outcomes with complication of diabetes, 827–9
β-cell mass in, 357
detection and diagnosis of diabetes, 13, 825–6, 828–9
drug therapy (insulin) see insulin administration
drug therapy (non-insulin/oral hypoglycemics), 830–1
glibenclamide compared with or as an alternative to insulin in, 626
metformin, 648, 830
epidemiology of diabetes, 824
exercise and diabetes in, 597, 605
fetus see fetus
glucose abnormalities, classification, 823–4
in utero environment see fetus
management/treatment of diabetes in, 828–9, 829–31
drugs see subentries above
new technologies, 831
maturity-onset diabetes of the young in glucokinase, 430–1
transcription factor MODY, 432–3
non-previously diagnosed diabetes see gestational diabetes
physiologic adaptations to, 823
previously diagnosed diabetes in see pregestational diabetes
retinopathy screening and management, 897
risk to child of later development with diabetes in, 41
special considerations, 831–2
see also fetus
prenatal factors see fetus
PrePACT study, 545
proprolin peptide mRNA see RNA
preproinsulin, 429
PREVERSE-Beta, 691
microvascular heart disease, 1070
Charcot neuroarthopathy, 972
microvascular heart disease, 1070
neonatal diabetes, 433
retinopathy, 890–1
neonatal diabetes, 433
retinopathy, 890–1
T2DM, 17–18
T2DM, 29–40
see also epidemiology
prevention (risk reduction) in elderly persons, 838–9
hypoglycemic crises (in hyperosmolar state and ketoadiposis), 812–13
hypoglycemic events, 793–4
macrovascular complications see macrovascular disease
microvascular see microvascular complications and specific types of microvascular complications
stroke, 1097–8
T2DM, 544–6
T2DM, 550–6, 631, 1121
cost-effectiveness, 557–8
drug-based drug-based prevention
exercise and see exercise
Index

screening
asymptomatic people, American Diabetic Association on, 999–1001
coronary heart disease patients (for diabetes and prediabetes), 1066–7
dental health professionals, 999–1001
foot ulcers, 971
gestational diabetes, 824–5, 858
HBAlc (for diabetes), 857
in pregnancy, 858
ne nephropathy, 918–9
older adults, 838
psychological problems, 850
retinopathy, 897
T2DM, 1121
SEARCH (for Diabetes) in Youth Study, 41, 443, 448
seasonality, 1057
T1DM and, 18
thrombosis and, 1057
secondary prevention
definition, 544
T1DM, 543
secretin, 153
several trends in T2DM prevalence, 36–9
sedentary lifestyle, 42–3
seeds, optimal amounts, 585
selective serotonin 2C (5-HT2C) receptor agonist, 499
self-management
internet-based see internet
older adults, 841–2
psychological problems, 850
self-reported periodontal disease, 982
sensory loss in diabetic foot, 966, 967
sensory neuropathies, islet, 130–1
serine-threonine phosphorylation, insulin receptor and IRS proteins, 180
severon 2C (5-HT2C) receptor agonist, selective, 499
serum proteins, glycation, 863–4
sex (gender)
anxiety and, 847
coronary heart disease and, 1012
acute myocardial infarction fatalities, 1013
nonalcoholic fatty liver disease and, 287
obstructive sleep apnea and, 317–18
nonalcoholic fatty liver disease and, 287
insulin resistance and, 180
oral antihyperglycemic agents and, 180
cardiovascular disease and, 1066
psychological problems, 850
sex-hormone binding globulin (SHBG) and insulin resistance and, 343, 344
sexual dysfunction in males see erectile dysfunction
SH2 domain-containing proteins, 167, 168, 381
SHARP (Study of Heart and Renal Protection) trial, 269–70
SHC proteins, 167–8, 381
Shh (Sonic Hedgehog), 58, 62
SHP1, 168
SHP2, 168, 172, 718
shoes/footwear and ulcers, 967, 971
short chain fatty acids, 474, 524–5
shoulder
adhesive capsulitis, 955–6
dystocia (baby), 832
shoulder–hand syndrome, 955–6, 958
Siberian native people, 35
sight (vision)-threatening retinopathy, prevalence, 890, 891
signal recognition particle (SRP), 87
signal transducers and activators of transcription see STAT
signal transduction
from insulin, 163–92, 225–6, 379–80, 381
atherogenesis and, 1038
drugs acting on, 716–18
hypothalamus and, 530, 533
insulin resistance and abnormalities in, 179–80, 379–80, 381, 879
modulation, 180–2
O-GlcNAc and, 419–20
insulin secretion and, 101–3
retinopathy and, 893
sildenafil
erectile dysfunction, 982, 984
nephropathy prevention, 568
Silent Diabetes Study, 1067
SWEETHEART Registry of, 1065, 1066
silver-impregnated dressings, 970
simvastatin, 267, 268, 270, 570, 899, 1097
Singapore Indian Eye study, 891
Singapore Malay Eye study, 891
single-nucleotide polymorphisms (SNPs)
hypertension and diabetes, 1080
T1DM, 460, 461–2
T2DM, 404, 407, 408
sirtuins, 204, 644, 723–4
sitagliptin, 543, 715, 733
structure, 741
in T1DM therapy, 543
in T2DM therapy with DPP-4 inhibitor, 692
with metformin, 692
skeletal complications, 953–4
skeletal muscle see muscle
skin
biopsy see biopsy
changes/disorders, 955
in Rosennbloom syndrome, 959, 960
foot, wound care, 969–70
skin substitutes with ulcers, 970
SLC see solute carrier family
Sleep, hypoglycemia during see nocturnal hypoglycemia
Sleep AHEAD study, 330, 331
sleep apnea, 316–36
central, 316, 331
obstructive see obstructive sleep apnea
Sleep Heart Health Study, 318, 319, 330, 331
smoking, 44–5
nephropathy and, 922
smooth muscle cells, vascular (VSMCs), and atherogenesis, 665, 1036, 1038
SNARE proteins, 99, 102, 177
social rights, 1106, 1107–8, 1111
socioeconomic impact of hypoglycemia, 790
SOCs-3 (suppressor of cytokine signaling-3), 182, 184
sodium (homeostasis)
extracellular, and hypertension, 1082
intracellular, and hypertension, 1080
see also natriuretic peptides
sodium–glucose transport protein/co-transporter-1 (SGLT1), 149, 387, 723
inhibitors, 723
sodium–glucose transport protein/co-transporter-2 (SGLT2), 387
inhibitors, 689, 712, 723
existing approved, 712
metformin and, 693
prevention of T2DM, 557
sodium–hydrogen (Na/H) antiporter activity, 1080
solute carrier family (SLC)
xxvi  Index

thromboembolic disease and nonalcoholic fatty liver disease, 289
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study, 1010–11
thrombolytic drugs in stroke, 1098
thrombosis, 1051–63
drugs preventing, 1058–9
glucose effects on, 1056
glycation effects on, 1056
inflammation and, 1057
pathogenesis (incl. mechanisms and factors leading to thrombosis), 1052–3
circadian variations, 1057
diabetes, 1014–15, 1032–3, 1053–6
thymoglobulin therapy in T1DM, 543
thyroid carcinoma and GLP-1 agonists, 738
tibial pulse (posterior) and peripheral vascular disease, 1092
ticagrelor, 1058–9, 1059
time trends in retinopathy epidemiology, 891–2
see also duration

tissue plasminogen activator (t-PA), 1052, 1053

tissue-restricted antigens (TRAs), 445, 446
tissue-targeted insulin receptor knockouts, 523–4
TNF-α see tumor necrosis-α
TODAY study (Treatment Options for type 2 Diabetes in Adolescents and Youth), 817–18, 820–1
tolbutamide, 625
cardiovascular mortality, 631
tolerance (immune)
central, 445
peripheral, 446
top-down approach to estimating costs, 1114–15

topiramate/phenetermine in nonalcoholic fatty liver disease, 296
tORC2 (cAMP-regulated transcriptional co-activator), 198
toxin-induced diabetes, 8–9
trace nutrients (micronutrients), dietary recommendations, 583
training, 598–601
in diabetes
adaptations to, 599–601
benefits, 601
guidelines, 605–6
in health, adaptations to, 598–9
strength, 598, 599, 601, 606
transcription in gluconeogenesis regulation, 198–9
insulin gene, regulation, 82–4, 85, 86, 87
insulin-regulated, 182–4
transcription factors

glucagon gene expression, 138

gluconeogenic gene expression, 198, 199
hyperthalamus, 530, 534
insulin gene expression, 82, 83, 84, 168, 182, 183, 194

lipogenic gene expression, 264
MODY (TF-MODY), 374, 426, 428, 429, 431–3
pancreatic and β-cell development, 57, 58, 59, 60, 61, 62, 64, 65
renal cysts and diabetes syndrome and, 436
T2DM and, 374, 375, 403, 407, 419
transdifferentiation to β-cells, 64
translation

insulin effects on, 182
preproinsulin mRNA, 87, 88–9
protein modifications following, 882–3
transplantation

islet and pancreas see islets; pancreas
stem cell see stem cell therapy
trans-unsaturated fatty acids (dietary), 579, 580
transurethral alprostadil, 984
treatment see management trial(s) or clinical trials
TriNet studies in T1DM preventive, 545
therapeutic, 542–3, 543
triamcinolone in retinopathy, 901–2
triacarbonylic acid (TCA; Krebs) cycle
β-cell, 97, 98
liver, 197, 292, 204, 206
trigger finger (flexor tenosynovitis), 955, 958
triglycerides (TGs), 262, 263–6
drugs lowering levels of, 722
drugs raising levels of, 760

elevated see hypertriglyceridaemia
intrahepatic, sources, 284–6
TRGK (Trial to Reduce Incidence of Diabetes in the Genetically at Risk), 544
Triunfrate (of insulin resistance in muscle and liver and β-cell failure), 373, 686, 688
triglycerides

Tumor necrosis factor (TNF-α), 180–1, 886

neurophroph and, 913
as therapeutic target, 886
T1DM, 543
twin studies

T1DM, 19, 454
T2DM, 402
type 1 DM (T1DM, IDDM), 401, 442–56

α-cells and, 141
β-cell loss, mechanisms, 74–6
β-cell monogenic disorders differentiated from, in young adults, 429
cancer and, 306–15
cerebrovascular disease and stroke in, 1013–15
children see adolescents; children classification/types, 5, 6, 7, 41
cost estimation, 114, 115, 116
diagnosis, 7, 29
early, 1119, 1121
diet see diet and nutrition
drug therapy, 877
α-glucosidase inhibitors, 674, 675, 678
biguanides (incl. metformin), 643–8, 820–1, 877
bromocriptine-QR, 762
colesevelam, 758, 759, 760, 761
combination see combination drug therapy
microvascular complications and, 877
obese adolescents, 820–1
sulfonylureas, 615, 621, 623, 624, 625, 628, 629, 630, 631, 632–3
thiazolidinediones see thiazolidinediones "treat-to-fail" approach, 694–5
epidemic, 401–2
epidemiology see epidemiology
exercise and see exercise
genetics, 401–12
β-cell failure, 6, 7, 375–6

genetic architecture, 17–28
established, 24
exercise and see exercise
family history and studies, 19, 454
glucotoxicity in, 421
HBA1c as unique index of glycemic control in, 858
isulin resistance in, 414
islet and pancreas transplantation see islets; pancreas
ketoacidosis in, epidemiology, 800
molecular genetics, 454–6
morphological disturbances of pancreas and islets, 73–4
neurophroph interventions (compared with T2DM), 919, 920, 922
natural history (compared with T2DM), 914
osteonin, 953–4
pathogenesis, 442–66
periodontal disease and effects of, 995
postprandial glucose disposal in, consequences of acute stimulatory effect of hyperglycemia on, 414
preventive trials, 544–6
protein metabolism in, 257
psychological problems

anxiety, 849
depression, 846
eating disorders, 848, 848–9
neurocognitive problems, 849
remission (honeymoon period), 24, 421, 599

treatment
artificial pancreas see artificial pancreas
pharmacological see drug-based therapy
trials, 541–4
tumor growth in, animal studies, 310–11
twin studies, 19, 454
type 2 DM (T2DM, NIDDM), 496
α-cells and, 141
animal models, 519–28
autonomic nerves and, 132
β-cell dysfunction in, 103, 358–65, 373–4, 375–6, 386
adolescents/young people and, 818
β-cell monogenic disorders differentiated from, in young adults, 429
cancer and, 306–15
cerebrovascular disease and stroke in, 1013–15
children see adolescents; children classification/types, 5, 6, 7, 41
cost estimation, 114, 115, 116
diagnosis, 7, 29
early, 1119, 1121
diet see diet and nutrition

natural history (compared with T2DM), 914
childhood, 818
renalcystsanddiabetessyndromeand, 436
mortalities

microvascular complications and, 877
obese adolescents, 820–1
sulfonylureas, 615, 621, 623, 624, 625, 628, 629, 630, 631, 632–3
thiazolidinediones see thiazolidinediones "treat-to-fail" approach, 694–5
epidemic, 401–2
epidemiology see epidemiology
exercise and see exercise
genetics, 401–12
β-cell failure, 6, 7, 375–6

genetic architecture, 17–28
established, 24
exercise and see exercise
family history and studies, 19, 454
glucotoxicity in, 421
immune-mediated see autoimmunity
incretin(s)
defect, 153–6, 361–3, 473
effects, 726–7
guidelines on use of incretin-based therapies, 740–2
insulin deficiency and, 374–5
insulin gene expression dysregulation and, 87
insulin pumps, 749, 753
insulin resistance see insulin resistance
ketoacidosis in, epidemiology, 800
lipid disturbances see dyslipidaemia
metabolomics, 273–80
morphological disturbances of pancreas and islets, 74
natural history, 372–3, 686
childhood, 818
neurophroph interventions (compared with T2DM), 919, 920, 922
natural history (compared with T2DM), 914–15
nonalcoholic fatty liver disease and risk of, 289
obesity-linked see obesity-linked type 2 diabetes
obstructive sleep apnea and, 324–9
impact of T2DM, 331
osteopenia, 954
pathogenesis see pathogenesis
postprandial glucose disposal in, consequences of acute stimulatory effect of hyperglycemia on, 414
prevention see prevention
proinsulin processing dysfunction, 92
protein metabolism in, 257–8
psychological problems
anxiety, 848
depression, 846
eating disorders, 848, 849
unconscious problems, 849
screening, 1121
treatment/management
drugs see subheading above
obesity-driven T2DM in youth, 820–1
pathophysiology and its implications for, 388, 688–9
periodontitis and effects of, 995
physical activity, 496
weight loss in, 486
tyrosine kinase activity of insulin receptors, 164–5, 177
vanadium supplements, 720
vapor-permeable dressings, 970
vardenafil, erectile dysfunction, 982, 984
variable number of tandem repeats (VNTR), insulin gene, 85, 445, 460
vascular cell adhesion molecule-1 (VCAM-1), 885
vascular endothelial growth factor (VEGF) and retinopathy
VEGF in pathogenesis, 893
VEGF inhibitors in management, 570–1, 900–1
vascular endothelial growth factor-2 receptor and cardiovascular events, 1047
vasculature
disease
diabetes and risk of, 1091
subtypes see cardiovascular disease;
 cerebrovascular disease; macrovascular disease; microvascular complications;
 peripheral vascular disease
endothelium see endothelium
foot, assessment, 968
islet, 71–2
penile, and erectile dysfunction, 977
retinal see retinal vessels
smooth muscle cells (VSMCs) and atherogenesis, 665, 1036, 1038
vasoactive intestinal polypeptide (VIP), 127
erec tile dysfunction and, 976
vasoactive intestinal polypeptide–pituitary adenylate cyclase-activating polypeptide receptors (VPAC), 127, 128, 132
vasodilation, insulin-induced, 251–2
vaspin, 719
vasoactive intestinal polypeptide; vascular endothelial growth factor; vascular endothelial growth factor-2 receptor
vascular endothelial growth factor-2 receptor
ventral pancreatic bud induction, 58
Veo® system, 753
vertical banded gastroplasty (VBG), 505–6, 508, 509
very-low-carbohydrate diets, 482, 494
very-low-density lipoprotein (VLDL), 262, 263, 264, 289
very-low-energy diets, 491
vesicle-associated membrane proteins (VAMP-2/VAMP3), 100, 177
Veterans Administration Genetic Epidemiology Study (VAGES), 373, 687
Veterans Affairs Diabetes Trial (VADT), 309, 565, 566, 878, 898, 1034, 1065, 1066, 1094, 1095
Veterans Affairs Feasibility Trial, 565, 566
Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), 266, 270
Veterans Affairs NEPHRON-D study, 1085
vildagliptin, 715, 733, 734, 740
pharmacologic characterization, 734
plus DPP-4 inhibitor, 692
plus metformin, 692
structure, 741
viral infections (as cause/in pathogenesis)
diabetes, 6, 9
T2DM, 22, 23, 446–7, 461
T2DM animal studies, 520
obesity, animal studies, 520
viscera (splanchnic tissues)
adiposity, 1032, 1033, 1042
insulin effects on protein metabolism, 255–6
visfatin, 719
vision-threatening retinopathy, prevalence, 890, 891
vitamin(s), 720
dietary recommendations, 583
fat-soluble, coenzyme and deficiency of, 760–1
therapeutic potential, 720
vitamin A receptor activator in nephropathy, 923
vitamin B12 deficiency, metformin-associated, 651
vitamin C and insulin resistance, 345
vitamin D insulin resistance and, 345
supplementation, 23, 545, 720
vitamin E in nonalcoholic fatty liver disease, 298
vitrectomy, 800, 802
VLDL (very-low-density lipoprotein), 262, 263, 264, 289
voglibose, 673, 674, 676
combined with diet therapy, 675
combined with other drugs, 676
prevention of T2DM, 677
von Willebrand factor (vWF), 1055
insulin resistance and, 345
W
waist circumference and abdominal obesity, 348, 349
“Walking Away from Type 2 Diabetes,” 559
Wald/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/National Heart, Lung, and Blood Institute (NHLBI)/American Diabetes Association (ADA)/International Diabetes Federation (IDF)/World Health Organization (WHO), 178
water
doubly-labelled, energy expenditure measurement using, 480
metabolism, in ketoacidosis and hyperosmolar state, 803
retention, sodiumuria-induced, 626
see also fluid therapy; hydration
weak-acid hydrolysis, total HbA1c measurement, 861
web-based self-management soaredinternet
weight (body), 479
at birth, excessive, 828
fetal, assessment, 831–2
gain
excessive see obesity
with insulin therapy, 794–5
with sulfonylureas, 630–1
with thiazolidinediones, 664, 669
GIP and, 153
loss/reduction (interventional), 267, 489–95
current recommendation in diabetes, 578, 579
maintaining, 495, 496
in nonalcoholic fatty liver disease, 293–4, 296, 296–7
pharmacological methods, 296, 496–502, 648–9, 678
Index

weight (body) (continued)
- prognostic markers of success and reasons for failure, 490–1
- surgical methods see bariatric surgery
  in T2DM prevention, 495, 552, 557
  in T2DM treatment, 496
  see also diet and nutrition
- neutrality of DPP-4 inhibitors, 736–7
- well-being, fetal, assessment, 831
Western Samoa, 34, 38
wheat, 22
WHO see World Health Organization
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 891, 892, 897
Wisconsin Sleep Cohort Study, 318, 329, 330
Wiskott–Aldrich syndrome proteins (WASPs), 178
Wolcott–Rallison syndrome and EIF2AK3 genes, 427, 434
Wolfram syndrome (DIDMOAD), 7, 427, 435, 437
women
- Convention on the Elimination of All Forms of Discrimination against Women, 1107, 1108
- coronary heart disease, 1011
- acute myocardial infarction fatalities, 1013
- postmenopausal, exercise and diabetes 597 females
  see women
- pregnant see pregnancy
Women’s Health Initiative (WHI), 306, 309, 310
World Health Organization (WHO)
  diabetes
    classification, 3, 3–4, 4
    diagnostic criteria, 29
    epidemic of, 1105
    obesity and, 470
    HbA1c, 551
- hyperension definitions (with ISH), 1007–8
- impaired glucose tolerance and fasting glucose, 550, 551
- metabolic syndrome
  diagnostic criteria, 347, 348, 1034
  utility of concept, 350–1
- Multinational Study of vascular disease in diabetes, 1015, 1097
- WOSCOPS, 268
- wound care (foot ulcers), 969–70
X
- X-ray plain films
  - Charcot neuroarthopathy, 972
  - periodontal disease, 989
  XENDOS trial, 555, 557
Y
- yellow mutation and obesity and cancer, 311
- youths/young adults see adolescents and youths/young adults
Z
- zebrafish model of endoderm induction and morphogenesis, 57
- Zucker fatty rats see fatty rats